Kura Oncology Statistics
Share Statistics
Kura Oncology has 77.76M shares outstanding. The number of shares has increased by 2.14% in one year.
| Shares Outstanding | 77.76M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.47% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 65.23M |
| Failed to Deliver (FTD) Shares | 51 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 8.89M, so 11.43% of the outstanding shares have been sold short.
| Short Interest | 8.89M |
| Short % of Shares Out | 11.43% |
| Short % of Float | 13.62% |
| Short Ratio (days to cover) | 3.32 |
Valuation Ratios
The PE ratio is -6.9 and the forward PE ratio is -6.96.
| PE Ratio | -6.9 |
| Forward PE | -6.96 |
| PS Ratio | 0 |
| Forward PS | 3.9 |
| PB Ratio | 2.65 |
| P/FCF Ratio | -8.42 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kura Oncology Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.26, with a Debt / Equity ratio of 0.04.
| Current Ratio | 12.26 |
| Quick Ratio | 12.26 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 4.15 |
| Cash Flow / Debt | -7.26 |
| Interest Coverage | -107.04 |
Financial Efficiency
Return on equity (ROE) is -0.38% and return on capital (ROIC) is -40%.
| Return on Equity (ROE) | -0.38% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -40% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.07M |
| Employee Count | 142 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -52.21% in the last 52 weeks. The beta is 0.86, so Kura Oncology 's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | -52.21% |
| 50-Day Moving Average | 11.79 |
| 200-Day Moving Average | 17.99 |
| Relative Strength Index (RSI) | 17.41 |
| Average Volume (20 Days) | 1.75M |
Income Statement
| Revenue | n/a |
| Gross Profit | -849.00K |
| Operating Income | -165.80M |
| Net Income | -152.63M |
| EBITDA | -164.96M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.08 |
Balance Sheet
The company has 37.32M in cash and 17.20M in debt, giving a net cash position of 20.12M.
| Cash & Cash Equivalents | 37.32M |
| Total Debt | 17.20M |
| Net Cash | 20.12M |
| Retained Earnings | -721.44M |
| Total Assets | 478.84M |
| Working Capital | 422.82M |
Cash Flow
In the last 12 months, operating cash flow was -124.82M and capital expenditures -168.00K, giving a free cash flow of -124.99M.
| Operating Cash Flow | -124.82M |
| Capital Expenditures | -168.00K |
| Free Cash Flow | -124.99M |
| FCF Per Share | -1.71 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -28.69% |
| FCF Yield | -22.15% |
Analyst Forecast
The average price target for KURA is $32, which is 341.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $32 |
| Price Target Difference | 341.4% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | 4.51 |
| Piotroski F-Score | 3 |